๐ก๐๐พ๐บ๐ ๐๐ฉ๐ณ๐ฐ๐ถ๐จ๐ฉ ๐ข๐บ๐๐ผ๐พ๐ is a foundation that empowers outstanding researchers and physicians to intercept the deadliest cancers.
breakthroughcancer.org
@break-cancer.bsky.social๐๐ฟ๐ฒ๐ฎ๐ธ ๐๐๐ง๐ค๐ช๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ
@break-cancer.bsky.social
@break-cancer.bsky.social@break-cancer.bsky.socialHow do we learn how treatment resistance emerges in pancreatic cancer? As Tyler Jacks told The New York Times today: by โdoing science in patients.โ Today Gina Kolata looks at the work bringing together leading cancer researchers to understand resistance to KRAS inhibition directly in patients.
@break-cancer.bsky.socialMore important than the number is how that research happens: across institutions, across disciplines and with a shared sense of urgency.
We call it radical collaboration. Because the hardest problems in cancer will take all of us.
@break-cancer.bsky.social#WorldCancerResearchDay is a reminder that progress against cancer depends on sustained investment.
At Break Through Cancer, we have committed over $137M since 2021 to research in acute myeloid leukemia, pancreatic cancer, ovarian cancer, glioblastoma, lung cancer, osteosarcoma and data science.
@break-cancer.bsky.socialAmong 30 patients with #AML undergoing bone marrow transplantation, all were considered to be in remission by standard criteria. Yet the new approach detected evidence of residual leukemia in every patient.
Read the study: www.pnas.org/doi/10.1073/...
#BloodCancerAwarenessMonth
@break-cancer.bsky.socialWhat if a blood test could find signs of leukemia that standard tests miss? In a new PNAS study, researchers from our Eradicating Measurable Residual Disease in AML TeamLab tested an approach that searches cell-free DNA in the blood for up to 96 mutations specific to each patientโs leukemia.
@break-cancer.bsky.socialThereโs a lot happening across Break Through Cancer.
New clinical trials. New discoveries. New collaborations bringing researchers together across institutions to tackle some of the deadliest cancers.
Stay connected: breakthroughcancer.org/contact/
#RadicalCollaboration #CancerResearch
@break-cancer.bsky.socialResearchers from our Eradicating Measurable Residual Disease in AML TeamLab have developed a personalized blood test that tracks up to 96 mutations specific to an individual patientโs leukemia.
Read the study: www.pnas.org/doi/10.1073/...
#AML #Leukemia #CancerResearch #RadicalCollaboration
@break-cancer.bsky.socialFor #BloodCancerAwarenessMonth, weโre highlighting new research aimed at finding the leukemia cells that can be hardest to see.
In AML, small numbers of cancer cells can remain after treatment, even when a patient is in remission. These residual cells can eventually lead to relapse.
@break-cancer.bsky.socialMark and Tyler discussed questions that become increasingly important as patients are treated with RAS inhibitors.
How do patients respond? How does resistance develop? What can we learn from patients to inform future treatment strategies?
@break-cancer.bsky.socialYesterdayโs FDA approval of Revolution Medicines' daraxonrasib/Rasonque marked an important moment for pancreatic cancer. But what happens next? Earlier this year, Mark Goldsmith, CEO of Revolution Medicines joined Tyler Jacks to discuss the science behind daraxonrasib.